Conformis Actera™ Hip System Receives 510(k) Clearance

 New design adds increasingly more common tri-taper femoral stem design and direct anterior approaches to the expanding Conformis family of Personalized Total Hip Arthroplasty implants

 Conformis, Inc. (NASDAQ:CFMS), a leading medical technology company featuring personalized knee and hip replacement products, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration for the Company’s Actera™ Hip System.

Actera adds a tri-taper femoral stem design to the expanding Conformis hip portfolio. This advanced tri-taper design is becoming more common among orthopedic surgeons, as its design objective is to facilitate a minimally invasive approach similar to direct anterior, with easier access to the femur and consequently less injury to muscles and fewer potential interactions with nerves.

https://finance.yahoo.com/news/conformis-actera-hip-system-receives-203000238.html